Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.

ABSTRACT:

Background

Chemotherapy is an integral part of the clinical management of triple negative breast cancer (TNBC), however, development of chemoresistance occurs frequently. Tumor sensitivity to treatment is known to be strongly influenced by the immune microenvironment, signifying the predictive potential of immune alterations. How tumor cells that acquire resistance may subsequently modulate the immune microenvironment it is still not well described. Here, we investigated immunomodulation in the context of acquired chemoresistance in TNBC, focusing on the role of the secretome.

Methods

Bulk RNA sequencing and multiplex cytokine profiling were performed on paclitaxel-resistant and -sensitive isogenic variants of TNBC cells to reveal resistance-associated secretome alterations.

SUBMITTER: Skourti E 

PROVIDER: S-EPMC12257726 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature